Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
3
×
boston blog main
boston top stories
deals
3
×
life sciences
national blog main
san francisco blog main
3
×
boston
national top stories
new york blog main
new york top stories
san francisco top stories
startups
vc
abbvie
acetylon pharmaceuticals
allergan
alzheimer's disease
ambys medicines
azacitidine
beta-thalassemia
cell therapy
clinical trials
constellation pharmaceuticals
crispr
cynthia collins
dacogen
decitabine
dna
editas medicine
epigenetics
epizyme
farydak
flagship pioneering
fulcrum therapeutics
gene editing
gene therapy
genentech
holger willenbring
insulated genomic domains
What
biotech
3
×
medicines
3
×
new
research
startup
abbvie
aiming
aims
alliance
ambys
approach
based
big
called
control
deadly
deal
debuted
debuts
developing
diseases
drugs
editas
editing
epigenetic
epigenetics
exits
experimental
field
flagship’s
formed
future
gene
genetic
launch
liver
make
morning
omega
pact
Language
unset
Current search:
deals
×
medicines
×
" san francisco blog main "
×
biotech
×
biotech
×
@xconomy.com
3 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?
